Glassy Mountain Advisors’s AbbVie ABBV Stock Holding History

Glassy Mountain Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-422	Closed	-$68.2K	–	18
2022 Q4	$68.2K	Buy	+422	New	+$64.7K	0.04%	106

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Glassy Mountain Advisors's ABBV Position: Q1 2023 in Review

Glassy Mountain Advisors sold out of AbbVie (ABBV) in Q1 2023, closing a stake of 422 shares — an estimated $68.2K sold.

Glassy Mountain Advisors first reported a position in ABBV in Q4 2022 and held it in 1 quarter. The position peaked at $68.2K in Q4 2022. 3,138 funds tracked by Wall St. Rank hold ABBV as of Q1 2023.

Glassy Mountain Advisors reported no remaining AbbVie position as of Q1 2023 after selling out during the quarter.
Glassy Mountain Advisors sold 422 AbbVie shares in Q1 2023, an estimated $68.2K.
Glassy Mountain Advisors first reported a position in AbbVie in Q4 2022 and held it in 1 quarter.
Glassy Mountain Advisors's AbbVie position peaked at $68.2K in Q4 2022.
3,138 funds tracked by Wall St. Rank held AbbVie as of Q1 2023.

Based on Glassy Mountain Advisors's 13F filing for Q1 2023, filed 27 Apr 2023.